MedTrace Logo

Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III

NCT01196260 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 8000

Last updated 2018-02-20

No results posted yet for this study

Summary

This study will examine a new combination of drugs: Capecitabine and Oxaliplatin for the treatment of Stage II and III colorectal cancer. Capecitabine and Oxaliplatin are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination has a positive effect on metastatic colorectal cancer.

Conditions

Interventions

DRUG

Capecitabine and Oxaliplatin

Capecitabine and Oxaliplatin will be under the NSCLC guideline

Sponsors & Collaborators

  • Tianjin Union Medical Center

    collaborator OTHER

  • Beihua University

    collaborator OTHER

  • Chengdu Medical College

    collaborator OTHER

  • Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • State Key Laboratory of Cancer Biology

    lead NETWORK

Principal Investigators

  • Dake Chu, M.D. · Air Force Military Medical University, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01196260 on ClinicalTrials.gov